$TCRX
TScan Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024124575 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3
Revenue $1.049M
YoY Change -73.01%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $7.409M
YoY Change 25.79%
% of Gross Profit
Research & Development $26.26M
YoY Change 15.48%
% of Gross Profit
Depreciation & Amortization $1.027M
YoY Change -19.77%
% of Gross Profit
Operating Expenses $33.67M
YoY Change 17.59%
Operating Profit -$32.62M
YoY Change 31.82%
Interest Expense $958.0K
YoY Change -2.44%
% of Operating Profit
Other Income/Expense, Net $2.735M
YoY Change 56.2%
Pretax Income -$29.89M
YoY Change 29.94%
Income Tax
% Of Pretax Income
Net Earnings -$29.89M
YoY Change 29.96%
Net Earnings / Revenue -2849.09%
Basic Earnings Per Share -$0.25
Diluted Earnings Per Share -$0.25
COMMON SHARES
Basic Shares Outstanding 118.7M
Diluted Shares Outstanding 118.7M

Balance Sheet

Concept 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $271.1M
YoY Change 25.87%
Cash & Equivalents $133.1M
Short-Term Investments $138.0M
Other Short-Term Assets $2.965M
YoY Change 41.19%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $274.1M
YoY Change 25.98%
LONG-TERM ASSETS
Property, Plant & Equipment $7.461M
YoY Change -13.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.807M
YoY Change 12.94%
Other Assets $5.031M
YoY Change 0.62%
Total Long-Term Assets $73.94M
YoY Change 0.18%
TOTAL ASSETS
Total Short-Term Assets $274.1M
Total Long-Term Assets $73.94M
Total Assets $348.0M
YoY Change 19.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.647M
YoY Change 14.11%
Accrued Expenses $14.83M
YoY Change 12.36%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change -100.0%
Total Short-Term Liabilities $28.66M
YoY Change -13.55%
LONG-TERM LIABILITIES
Long-Term Debt $30.65M
YoY Change 6.28%
Other Long-Term Liabilities $146.0K
YoY Change 1116.67%
Total Long-Term Liabilities $30.79M
YoY Change 6.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.66M
Total Long-Term Liabilities $30.79M
Total Liabilities $118.9M
YoY Change -2.84%
SHAREHOLDERS EQUITY
Retained Earnings -$339.3M
YoY Change 48.82%
Common Stock $568.4M
YoY Change 43.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $229.1M
YoY Change
Total Liabilities & Shareholders Equity $348.0M
YoY Change 19.44%

Cashflow Statement

Concept 2024 Q3
OPERATING ACTIVITIES
Net Income -$29.89M
YoY Change 29.96%
Depreciation, Depletion And Amortization $1.027M
YoY Change -19.77%
Cash From Operating Activities -$27.92M
YoY Change -448.1%
INVESTING ACTIVITIES
Capital Expenditures $1.370M
YoY Change -3.52%
Acquisitions
YoY Change
Other Investing Activities -$80.98M
YoY Change 34.97%
Cash From Investing Activities -$82.35M
YoY Change 34.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.230M
YoY Change -573.08%
NET CHANGE
Cash From Operating Activities -27.92M
Cash From Investing Activities -82.35M
Cash From Financing Activities 1.230M
Net Change In Cash -109.0M
YoY Change 103.25%
FREE CASH FLOW
Cash From Operating Activities -$27.92M
Capital Expenditures $1.370M
Free Cash Flow -$29.29M
YoY Change -543.76%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001783328
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.tscan.com/20240930#CollaborationAndLicenseRevenue
CY2023Q3 us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.tscan.com/20240930#CollaborationAndLicenseRevenue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.tscan.com/20240930#CollaborationAndLicenseRevenue
us-gaap Revenue From Contract With Customer Product And Service Extensible List
RevenueFromContractWithCustomerProductAndServiceExtensibleList
http://www.tscan.com/20240930#CollaborationAndLicenseRevenue
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40603
dei Entity Registrant Name
EntityRegistrantName
TSCAN THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5282075
dei Entity Address Address Line1
EntityAddressAddressLine1
830 Winter Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
399-9500
dei Security12b Title
Security12bTitle
Voting Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
TCRX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133118000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133359000
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
138002000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
58685000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2965000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2193000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
274085000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
194237000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7461000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7742000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
59643000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
63492000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5031000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5031000
CY2024Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1807000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1647000
CY2024Q3 us-gaap Assets
Assets
348027000
CY2023Q4 us-gaap Assets
Assets
272149000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3647000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2374000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11181000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10716000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3898000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3246000
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9934000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10137000
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
3347000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
28660000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
29820000
CY2024Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3676000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
5622000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
55811000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
59140000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
30647000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
26700000
CY2024Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
146000
CY2024Q3 us-gaap Liabilities
Liabilities
118940000
CY2023Q4 us-gaap Liabilities
Liabilities
121282000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
568368000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
398459000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339287000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-247597000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
229087000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
150867000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
348027000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
272149000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1049000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3887000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2151000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
13838000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26262000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22741000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
77996000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
65747000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7409000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5894000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22264000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20192000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
33671000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
28635000
us-gaap Operating Expenses
OperatingExpenses
100260000
us-gaap Operating Expenses
OperatingExpenses
85939000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32622000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24748000
us-gaap Operating Income Loss
OperatingIncomeLoss
-98109000
us-gaap Operating Income Loss
OperatingIncomeLoss
-72101000
CY2024Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
3693000
CY2023Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
2733000
us-gaap Interest And Other Income
InterestAndOtherIncome
9288000
us-gaap Interest And Other Income
InterestAndOtherIncome
5403000
CY2024Q3 us-gaap Interest Expense
InterestExpense
958000
CY2023Q3 us-gaap Interest Expense
InterestExpense
982000
us-gaap Interest Expense
InterestExpense
2869000
us-gaap Interest Expense
InterestExpense
2907000
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2735000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1751000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6419000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2496000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29887000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22997000
us-gaap Net Income Loss
NetIncomeLoss
-91690000
us-gaap Net Income Loss
NetIncomeLoss
-69605000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118700362
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118700362
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94829844
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94829844
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109035938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109035938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55711252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55711252
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
190607000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1342000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22997000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
168961000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
255221000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1230000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2523000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29887000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
229087000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
99434000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
692000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
42414000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
92318000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3708000
us-gaap Net Income Loss
NetIncomeLoss
-69605000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
168961000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
150867000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1672000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
33131000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
128272000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6835000
us-gaap Net Income Loss
NetIncomeLoss
-91690000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
229087000
us-gaap Profit Loss
ProfitLoss
-91690000
us-gaap Profit Loss
ProfitLoss
-69605000
us-gaap Depreciation
Depreciation
3397000
us-gaap Depreciation
Depreciation
4081000
tcrx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-2347000
tcrx Accretion Of Marketable Securities
AccretionOfMarketableSecurities
-235000
tcrx Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
600000
tcrx Noncash Interest Expense On Notes Payable
NoncashInterestExpenseOnNotesPayable
655000
us-gaap Share Based Compensation
ShareBasedCompensation
6835000
us-gaap Share Based Compensation
ShareBasedCompensation
3708000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
932000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1034000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
995000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
543000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1011000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
589000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
870000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
2542000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2149000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
19096000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-83410000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37592000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2937000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2677000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
194116000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
59995000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
117147000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79906000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-62672000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33131000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42414000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
128272000
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
92318000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1672000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
692000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
163075000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
135424000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-241000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
35160000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138390000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
125064000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138149000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160224000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
133118000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
155193000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5031000
CY2023Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
5031000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138149000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
160224000
us-gaap Interest Paid Net
InterestPaidNet
2269000
us-gaap Interest Paid Net
InterestPaidNet
2261000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
480000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
343000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-04-17
us-gaap Net Income Loss
NetIncomeLoss
-91700000
us-gaap Net Income Loss
NetIncomeLoss
-69600000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-339300000
CY2024Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
262141000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
187467000
CY2024Q3 tcrx Fair Value Asset Level1 To Level2 Transfers Amount
FairValueAssetLevel1ToLevel2TransfersAmount
0
CY2024Q3 tcrx Fair Value Asset Level2 To Level1 Transfers Amount
FairValueAssetLevel2ToLevel1TransfersAmount
0
CY2023Q4 tcrx Fair Value Asset Level1 To Level2 Transfers Amount
FairValueAssetLevel1ToLevel2TransfersAmount
0
CY2023Q4 tcrx Fair Value Asset Level2 To Level1 Transfers Amount
FairValueAssetLevel2ToLevel1TransfersAmount
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2024Q3 tcrx Accrued Research And Development
AccruedResearchAndDevelopment
4980000
CY2023Q4 tcrx Accrued Research And Development
AccruedResearchAndDevelopment
3537000
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4798000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5478000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
896000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1026000
CY2024Q3 tcrx Accrued Legal Services And License Fee Current
AccruedLegalServicesAndLicenseFeeCurrent
259000
CY2023Q4 tcrx Accrued Legal Services And License Fee Current
AccruedLegalServicesAndLicenseFeeCurrent
250000
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
248000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
425000
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11181000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
10716000
CY2023Q2 tcrx Proceeds From Issuance Of Common Stock And Warrants Net Of Underwriting Discounts And Expenses
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfUnderwritingDiscountsAndExpenses
134700000
CY2023Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
42400000
CY2023Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
92300000
CY2024Q2 tcrx Proceeds From Issuance Of Common Stock And Warrants Net Of Underwriting Discounts And Expenses
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfUnderwritingDiscountsAndExpenses
161400000
CY2024Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
33100000
CY2024Q2 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
128300000
CY2022Q3 tcrx Default Interest Rate
DefaultInterestRate
0.05
CY2024Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1000000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2900000
CY2023Q3 us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1000000
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
2900000
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.1257
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
9659000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
20341000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2024Q3 tcrx Long Term Debt Final Payment Fee
LongTermDebtFinalPaymentFee
1800000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1153000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
30647000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-29887000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22997000
us-gaap Net Income Loss
NetIncomeLoss
-91690000
us-gaap Net Income Loss
NetIncomeLoss
-69605000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
118700362
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
118700362
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
94829844
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
94829844
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
109035938
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109035938
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
55711252
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
55711252
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.25
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.25
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18784955
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16788371
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 tcrx Rule10 B51 Arr Modified Flag
Rule10B51ArrModifiedFlag
false
CY2024Q3 tcrx Non Rule10 B51 Arr Modified Flag
NonRule10B51ArrModifiedFlag
false

Files In Submission

Name View Source Status
0000950170-24-124575-index-headers.html Edgar Link pending
0000950170-24-124575-index.html Edgar Link pending
0000950170-24-124575.txt Edgar Link pending
0000950170-24-124575-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrx-20240930.htm Edgar Link pending
tcrx-20240930.xsd Edgar Link pending
tcrx-ex31_1.htm Edgar Link pending
tcrx-ex31_2.htm Edgar Link pending
tcrx-ex32_1.htm Edgar Link pending
tcrx-ex32_2.htm Edgar Link pending
tcrx-20240930_htm.xml Edgar Link completed